Navigation Links
FDA Moves to Stop Bogus Products Sold Over the Counter and Online that Falsely Claim to Cure and Treat STDs
Date:5/4/2011

WASHINGTON, May 4, 2011 /PRNewswire-USNewswire/ -- "The public's health has won out over the actions of a few unscrupulous manufacturers that put profit first," said Dr. Jane L. Delgado, President and CEO of the National Alliance for Hispanic Health (the Alliance), the nation's leading Hispanic health advocacy group. Commenting on actions taken by the Food and Drug Administration (FDA) in concert with the Federal Trade Commission (FTC) to halt fraudulent claims, Dr. Delgado stated, "Stopping manufacturers from making unproven claims to prevent, treat, or cure sexually transmitted diseases (STDs) was the right thing to do. Consumers with concerns about STDs should see their health provider for testing and appropriate prescribed medication or vaccinations."

FDA-approved drugs and vaccines for the treatment and prevention of STDs can only be obtained by prescription through a licensed healthcare professional. Currently there are no FDA-approved drugs or dietary supplements available over-the-counter (OTC) that can prevent, cure, and/or treat STDs. Condoms are the only OTC products cleared by FDA to help prevent sexually transmitted infections. According to the FDA, fraudulent STD products are being sold primarily over the Internet, but some are also available in local retail stores. Marketers of fraudulent STD products are in violation of the Federal Food, Drug, and Cosmetic Act.

According to the FDA and FTC, some fraudulent STD products that have been identified include H-Stop Dx, H-Guard Dx, Wart Dx, Molluscum Dx, EverCLR3, Herpeset, C-Cure, Viruxo, Medavir, and Wartrol. A dozen firms have received warning letters requiring all unapproved claims be stopped. Firms that do not correct the violations may face enforcement action, possible legal penalties, and criminal prosecution. Additionally, FDA and FTC are warning consumers and healthcare professionals not to purchase or use these fraudulent STD products.

"Those using products not prescribed by their health provider for STDs are putting their health and that of their sexual partners at risk. We are here to help with information on STDs, what fraudulent products are included in today's action, and referral to health providers in your community," emphasized Dr. Delgado. Information is available free of charge from the Alliance's bilingual and toll-free Su Familia National Hispanic Family Health Helpline (1-866-783-2645 or 1-866-SU-FAMILIA) as well as on the Alliance's website (www.hispanichealth.org).

About the National Alliance for Hispanic Health

The National Alliance for Hispanic Health is the nation's foremost science-based source of information and trusted advocate for the health of Hispanics in the United States. The Alliance represents thousands of Hispanic health providers across the nation providing services to more than 15 million each year, making a daily difference in the lives of Hispanic communities and families. For more information, visit www.hispanichealth.org or call 1-866-783-2645.

Contact: Adam J. Segal, 202.422.4673 or media@hispanichealth.org


'/>"/>
SOURCE National Alliance for Hispanic Health
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Arriva Pharmaceuticals Moves Forward to Phase 2b Development of Lead Inhaled Protein rAAT Replacement Therapy for Hereditary Emphysema
2. Trellis(R) Catheter Removes Blood Clots Quickly, Restoring Blood Flow in 771 Deep Vein Thrombosis (DVT) Patients
3. Neutropenia: Biosimilar Product from India Moves One Step Closer to European Market
4. Roche Moves Investigational Diabetes Drug, Taspoglutide, Into Phase III Clinical Trials
5. Debiopharm Moves Towards a New 6-Month Formulation of Decapeptyl(R) to Further Help Prostate Cancer Patients
6. Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series
7. GHX Health ConneXion(TM) Data Pool Gains Momentum as Healthcare Industry Moves Toward Standards Adoption
8. CareFusion Moves First Quarter Earnings Announcement to November 5
9. Access MediQuip Moves Company Headquarters to Lake Mary, Florida
10. China Sky One Medical, Inc. Completes and Moves into New Corporate Headquarters
11. Instacare Moves to Secure Patents for Its Newest Technologies, Announces Parallel Strategies for Its Revolutionary MD@Hand Cell-Centric Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... --  ZappRx, Inc ., a digital health company focused on ... it closed $25 million in Series B funding led by ... Seattle that is part of a ... B round included participation from SR One , who ... (formerly Google Ventures). As part of the financing, ...
(Date:4/20/2017)... , April 20, 2017 Eyevensys, ... the first non-viral gene expression technology that enables the ... eye to address a wide range of ophthalmic diseases, ... and Healthcare products Regulatory Agency (MHRA) to advance its ... ...
(Date:4/19/2017)... - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), announces that ... Conference 2017 at the Sheraton Hotel in Toronto, Ontario ... of the Company is scheduled to present on Tuesday, May 2 ... the Chairman of the Board, Tony Holler will also ... For more ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... 2017 , ... Accreditation Commission for Health Care (ACHC) is ... (HCAOA). This agreement allows HCAOA members to receive special pricing on ACHC’s Home ... University (AU) educational resources that help prepare HCAOA members for ACHC Accreditation. , ...
(Date:4/28/2017)... Clara, CA (PRWEB) , ... April 28, 2017 ... ... is pleased to announce the integration of Microsoft(R) Word(TM) Online(TM), which enables sleep ... user experience, since it streamlines the reporting process and provides a familiar interface ...
(Date:4/28/2017)... ... ... Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) announced today that ... as “stable.” At the same time, the ratings agency cautioned that the company’s rating ... “capital adequacy” thresholds required for its strong rating. , “Horizon is committed to being ...
(Date:4/28/2017)... ... April 28, 2017 , ... GlycoMark, ... the GlycoMark test throughout the Northeast U.S. , GlycoMark is the only ... The GlycoMark test provides a clinically proven one- to two-week measure of hyperglycemic ...
(Date:4/28/2017)... ... 2017 , ... Ushio America proudly introduces the new ... solution for F32T8 fluorescent lamps on most instant-start and programmed-start electronic ballasts so ... lamps utilize the existing electronic ballast, saving labor and maintenance costs. It’s easy ...
Breaking Medicine News(10 mins):